Lv41
790 积分 2022-11-04 加入
Does SLC39A8 Ala391Thr Confer Risk of Chronic Liver Disease?
2小时前
待确认
Reply Re: “Teprotumumab for the Treatment of Recalcitrant Thyroid Eye Disease”
3小时前
求助中
Re: “Teprotumumab for the Treatment of Recalcitrant Thyroid Eye Disease”
3小时前
求助中
Enrichment of IGF-1R and PPARγ signalling pathways in orbital inflammatory diseases: steps toward understanding pathogenesis
4小时前
已完结
Efficacy and Safety of CBL-514 Injection in Reducing Abdominal Subcutaneous Fat: A Randomized, Single-Blind, Placebo-Controlled Phase II Study
7天前
已完结
Pharmacokinetic and Pharmacodynamic Modeling of siRNA Therapeutics – a Minireview
7天前
已完结
Mechanistic Pharmacokinetics and Pharmacodynamics of GalNAc-siRNA: Translational Model Involving Competitive Receptor-Mediated Disposition and RISC-Dependent Gene Silencing Applied to Givosiran
7天前
已完结
Predicting Clinical Pharmacokinetics/Pharmacodynamics and Impact of Organ Impairment on siRNA‐Based Therapeutics Using a Mechanistic Physiologically‐Based Pharmacokinetic‐Pharmacodynamic Model
7天前
已完结
Advances in obesity pharmacotherapy; learning from metabolic surgery and beyond
7天前
已完结
Identification and validation of INHBE and P4HA1 as hub genes in non-alcoholic fatty liver disease
7天前
已完结
皖公网安备34019202002308
